Health related quality of life impact from rotavirus diarrhea on children and their family caregivers in Thailand.

Abstract:

BACKGROUND:Rotavirus diarrhea is a major health problem among young children worldwide with potential negative impacts on health-related quality of life (HRQoL). This study assessed the impact of rotavirus diarrhea on HRQoL of children and their caregivers. METHODS:We performed a cross-sectional study among 460 hospitalized children with diarrhea aged under 5 years and their family caregivers at three hospitals in Phetchabun province, Thailand during May 2013 and February 2014. The severity of diarrhea was assessed using the Vesikari severity scoring system while the HRQoL was assessed using the EQ-5D-3L. RESULTS:The mean EQ-5D utility of children with all-causes diarrhea was 0.604. The utility of the rotavirus diarrhea group was significantly lower than that of the non-rotavirus diarrhea group (0.593 vs. 0.612; p-value = 0.040). The family caregiver's utility was 0.964 at baseline and significantly decreased to 0.620 (p-value = 0.041) when their children were hospitalized with diarrhea. In multiple regression analyses, severity but not rotavirus infection had significant negative impacts on the utility of both the children and their caregivers. CONCLUSION:Diarrhea, either caused by rotavirus or non-rotavirus infection, resulted in substantial negative impacts on the quality of life of both the children and their caregivers.

authors

Rochanathimoke O,Riewpaiboon A,Postma MJ,Thinyounyong W,Thavorncharoensap M

doi

10.1080/14737167.2018.1386561

subject

Has Abstract

pub_date

2018-04-01 00:00:00

pages

215-222

issue

2

eissn

1473-7167

issn

1744-8379

journal_volume

18

pub_type

杂志文章,多中心研究
  • Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan.

    abstract:OBJECTIVE:To assess the cost-effectiveness of single pill fixed dose triple combination therapy vs. free triple combination therapy for the prevention of cardiovascular events among patients with hypertension. METHODS:A Markov model with a five year cycle was constructed. Two decision models incorporating strict and m...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2020.1800457

    authors: Wang X,Chen H,Ej E,Wu J,Serna O,Paranjpe R,Abughosh S

    更新日期:2020-08-01 00:00:00

  • Cost-effectiveness of bronchial thermoplasty in commercially-insured patients with poorly controlled, severe, persistent asthma.

    abstract:OBJECTIVES:We examined the cost-effectiveness of treating poorly controlled, severe, persistent asthma patients with bronchial thermoplasty (BT), a novel technology that uses thermal energy to reduce airway smooth muscle mass, with 5-year outcome data demonstrating a durable reduction in asthma exacerbations. STUDY DE...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.2015.978292

    authors: Cangelosi MJ,Ortendahl JD,Meckley LM,Bentley TG,Anene AM,Shriner KM,Fox J

    更新日期:2015-04-01 00:00:00

  • Promoting pan-European cancer research for the benefit of all cancer patients.

    abstract::The European Organisation for Research and Treatment of Cancer (EORTC) 50th Anniversary Conference was held on the 15-16 March in Brussels, Belgium. More than 1100 participants (including EORTC members and staff, national research organizations, health authorities, patient advocacy groups, European Commission, cancer ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type:

    doi:10.1586/erp.12.32

    authors: Bean J,Bottomley A,Meunier F

    更新日期:2012-08-01 00:00:00

  • Economic considerations and future directions for lung volume reduction surgery.

    abstract::Chronic obstructive pulmonary disease is a major cause of morbidity and mortality throughout the world. Standard management includes avoidance of causative factors such as smoking, and pharmacological therapy with combinations of inhaled and/or oral bronchodilators and corticosteroids. Lung transplantation is an estab...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.3.6.729

    authors: Reed A,Williams T,Snell G

    更新日期:2003-12-01 00:00:00

  • A systematic review of the cost-effectiveness of peginterferon alfa-2b in the treatment of chronic hepatitis C.

    abstract::A systematic review was conducted of the full economic evaluations of the cost-effectiveness of peginterferon alfa-2b (PEG-IFN alfa-2b) plus ribavirin (RBV) in the treatment of chronic hepatitis C (CHC). A total of 439 references were screened and 11 studies were included. The studies employed decision analytic Markov...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.7.6.577

    authors: Shepherd J,Jones J

    更新日期:2007-12-01 00:00:00

  • Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review.

    abstract::Ankylosing spondylitis (AS) is a complex systemic rheumatological disease which often causes severe disability and impaired quality of life (QoL). We searched the PubMed/MEDLINE electronic database for available literature on QoL and its predictors in patients with AS. Recent evidence indicates that AS patients have p...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.2014.957679

    authors: Kotsis K,Voulgari PV,Drosos AA,Carvalho AF,Hyphantis T

    更新日期:2014-12-01 00:00:00

  • Should the patent system for pharmaceuticals be replaced? A theoretical approach.

    abstract::This paper acknowledges the difficulties of providing access to innovative drugs in some jurisdictions under the patent system and it contributes to the current debate on mechanisms aimed at facilitating such access. We employ a highly stylized static model of two markets (North and South) to analyse the conditions un...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.2014.927315

    authors: Antoñanzas F,Rodríguez-Ibeas R,Juárez-Castelló CA

    更新日期:2014-10-01 00:00:00

  • A survey of individuals in US-based pharmaceutical industry HEOR departments: attitudes on policy topics.

    abstract::We surveyed US-based leaders in health economics and outcomes research (HEOR) departments in drug and device companies to examine their views on the state of the field. We created a questionnaire that was emailed to 123 US-based senior HEOR professionals at 54 companies. Of the 123 recipients, 74 (60%) completed the s...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.2013.838027

    authors: Neumann PJ,Saret CJ

    更新日期:2013-10-01 00:00:00

  • Cost analysis and clinical applicability of the Resonance metallic ureteral stent.

    abstract::The Resonance metallic stent is a new wire-based ureteral stent that was initially developed for patients with malignant ureteral obstruction. Potential advantages over traditional stents include resistance to encrustation and to external compression, allowing for increased dwell times and the maintenance of upper tra...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/erp.09.74

    authors: Polcari AJ,Hugen CM,López-Huertas HL,Turk TM

    更新日期:2010-02-01 00:00:00

  • Application of electronic medical record data for health outcomes research: a review of recent literature.

    abstract::Electronic medical records (EMRs) have become a common source of data for outcomes research. This review discusses trends in EMR data use for outcomes research as well as strengths and limitations, and likely future developments to help optimize value and use of EMR data for outcomes research. EMR-based studies report...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.13.7

    authors: Lin J,Jiao T,Biskupiak JE,McAdam-Marx C

    更新日期:2013-04-01 00:00:00

  • Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis.

    abstract:BACKGROUND:This study aims to report on the design of a model to determine the cost-effectiveness of prevention and treatment of early psychosis (PsyMod) and to estimate ten-year cost-effectiveness and budget impact of interventions targeting individuals with ultra-high risk (UHR) of developing psychosis or with first ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2019.1632194

    authors: Wijnen BFM,Thielen FW,Konings S,Feenstra T,Van Der Gaag M,Veling W,De Haan L,Ising H,Hiligsmann M,Evers SMAA,Smit F,Lokkerbol J

    更新日期:2020-06-01 00:00:00

  • Radiotherapy cost-calculation and its impact on capacity planning.

    abstract::The rapid rise in health care expenses has resulted in an increased interest in the cost of treatments from a cost-effectiveness point of view for management purposes and in a reimbursement setting. The economics of radiotherapy within the global context of health care, and more specifically of cancer therapy, are dis...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.3.4.497

    authors: Lievens Y,Slotman BJ

    更新日期:2003-08-01 00:00:00

  • Methods and issues associated with the use of quality-adjusted life-years.

    abstract::In this article, we will focus on how preferences and utilities are measured, including the strengths and limitations of various approaches, discuss their use in estimating quality-adjusted life-years (QALYs) and make some recommendations for further research. Preferences are either measured using direct (visual analo...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.11.100

    authors: Revicki DA,Lenderking WR

    更新日期:2012-02-01 00:00:00

  • Short- and long-term HRQOL issues following brachytherapy for prostate cancer.

    abstract::Given the lack of evidence from randomized controlled trials and large prospective studies, controversy exists regarding the optimal treatment strategy for early stage prostate cancer. The impact of various treatments on health-related quality of life has become an increasingly important but controversial issue. The l...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.4.3.277

    authors: D'haese S,Bottomley A

    更新日期:2004-06-01 00:00:00

  • Interferon-alpha in high-risk melanoma patients.

    abstract::The incidence of melanoma has been climbing steadily since the early 1970s. Although melanoma can be successfully cured by surgical excision in its early stages, it is the most common fatal form of skin cancer. The most critical factors in determining the prognosis for patients with melanoma are primary tumor thicknes...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.4.6.667

    authors: Cormier JN,Xing Y,Ross MI,Cantor SB

    更新日期:2004-12-01 00:00:00

  • Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban.

    abstract::This paper reviews the clinical and pharmacoeconomic studies that have been conducted within Europe for patients undergoing elective hip-replacement surgery. Additionally, we offer a perspective on the possible future clinical use of new agents in orthopedic surgery, such as dabigatran and BAY 59-7939 (rivaroxban). Lo...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.7.1.49

    authors: Ivanovic N,Beinema M,Brouwers JR,Naunton M,Postma MJ

    更新日期:2007-02-01 00:00:00

  • Cost-effectiveness of palivizumab in infancy.

    abstract::Respiratory syncytial virus is the most common cause of bronchiolitis, a lower respiratory tract infection occurring in infancy. It is responsible for several rehospitalizations, substantial morbidity and occasional deaths in the UK every year. Palivizumab is a recombinant monoclonal antibody that has been shown to re...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.7.5.445

    authors: Embleton ND,Dharmaraj ST,Deshpande S

    更新日期:2007-10-01 00:00:00

  • Health-related quality of life in patients with acute coronary syndromes and treated with ticagrelor or clopidogrel.

    abstract::Evaluation of: Levin LA, Wallentin L, Bernfort L et al. Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes results from the PLATO trial. Value Health 16(4), 574-580 (2013). Antiplatelet therapy is considered essential treatment for acute coronary syndromes with or...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 评论,杂志文章

    doi:10.1586/14737167.2014.861743

    authors: De Franco AC,Oldridge N

    更新日期:2014-02-01 00:00:00

  • Symptom clusters in patients with metastatic cancer: a literature review.

    abstract::This article reviews the literature reporting empirically determined symptom clusters in patients with metastatic cancer. A literature search was conducted on symptom clusters within heterogeneous metastatic cancer patient populations using MEDLINE, EMBASE, and CINAHL. Studies examining predetermined symptom clusters ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.12.41

    authors: Thavarajah N,Chen E,Zeng L,Bedard G,Di Giovanni J,Lemke M,Lauzon N,Zhou M,Chu D,Chow E

    更新日期:2012-10-01 00:00:00

  • Effectiveness of non-pharmacological COPD management on health-related quality of life - a systematic review.

    abstract::Introduction: Chronic obstructive pulmonary disease (COPD) is the third leading cause of mortality worldwide. The chronic progressive disease is accompanied by a high loss of health-related quality of life (HRQoL). The available drugs usually only have symptomatic effects; therefore, non-pharmacological therapies are ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2020.1734455

    authors: Hindelang M,Kirsch F,Leidl R

    更新日期:2020-02-01 00:00:00

  • How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 3/3).

    abstract:INTRODUCTION:This article is part of the series "How to Prepare a Systematic Review (SR) of Economic Evaluations (EE) for Informing Evidence-based Healthcare Decisions" in which a five-step-approach for conducting a SR of EE is proposed. Areas covered: This paper explains the data extraction process, the risk of bias a...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1080/14737167.2016.1246961

    authors: Wijnen B,Van Mastrigt G,Redekop WK,Majoie H,De Kinderen R,Evers S

    更新日期:2016-12-01 00:00:00

  • Health status and costs of exacerbations of chronic bronchitis and COPD: how to improve antibiotic treatment.

    abstract::Up to 10% of the adult population in most countries may be affected by chronic bronchitis or chronic obstructive pulmonary disease. The course of the disease is characterized by frequent exacerbations with increased respiratory symptoms. Exacerbations are the most important cause of morbidity and mortality, and signif...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.5.4.423

    authors: Miravitlles M

    更新日期:2005-08-01 00:00:00

  • National trends in out-of-pocket prescription drug spending among elderly medicare beneficiaries.

    abstract::This review examines the national trends in out-of-pocket and high economic burden of prescription drug expenditures by elderly people aged 65 years and older. From 1992 to 2000, prescription out-of-pocket drug expenditures increased at an annual rate of 7%. During this period the proportion of elderly without prescri...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.5.3.297

    authors: Sambamoorthi U,Akincigil A,Wei W,Crystal S

    更新日期:2005-06-01 00:00:00

  • Looking for Her (2+): A systematic review of the economic evaluations of Trastuzumab in early stage HER 2 positive breast cancer.

    abstract:INTRODUCTION:Breast cancer, the second most common cancer in women, exerts a multidimensional grave effect on affected women. Among the several subtypes of breast cancer, the overexpression of the human epidermal growth factor receptor-2 gene is associated with poorer survival and higher relapse rates. Trastuzumab, a m...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2019.1536549

    authors: Petrou P

    更新日期:2019-04-01 00:00:00

  • Corneal transplantation using the Descemet's stripping endothelial keratoplasty technique.

    abstract::Descemet's stripping endothelial keratoplasty (DSEK) is a relatively new technique that is rapidly replacing full-thickness procedures for those patients needing corneal transplantation for endothelial dysfunction. Benefits of DSEK include a faster recovery, reduced astigmatism, fewer postoperative complications and r...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.7.2.137

    authors: Kharod BV,Carlson AN

    更新日期:2007-04-01 00:00:00

  • Metastatic melanoma in the older patient: immunologic insights and treatment outcomes.

    abstract::Cutaneous melanoma (CM) is a highly curable skin cancer of melanocytes if diagnosed early. Unfortunately, its invasion into the deeper dermis increases the risk of it spreading to the lymph nodes and distant organs. Spread of metastatic melanoma (MM) to other organs is among one of the most dangerous conditions that i...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.11.14

    authors: Hegde UP,Chakraborty N,Mukherji B,Grant Kels JM

    更新日期:2011-04-01 00:00:00

  • Prevalence, awareness, and burden of major depressive disorder in urban China.

    abstract:OBJECTIVES:This cross-sectional study examined the prevalence and burden of major depressive disorder (MDD) among adults in urban China. METHODS:Data were included from the 2012 China National Health and Wellness Survey. Respondents self-reporting physician diagnosis of depression and screening positive for MDD (Patie...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.2016.1102062

    authors: Gupta S,Goren A,Dong P,Liu D

    更新日期:2016-06-01 00:00:00

  • Converting condition-specific measures into preference-based outcomes for use in economic evaluation.

    abstract::Quality-adjusted life-years (QALYs) play an important role in reimbursement decisions when one of the criteria is the cost-effectiveness of the health technology. While for many generic QALYs (e.g., based on the EQ-5D) are viewed as the gold standard, there has been a considerable increase in interest in using conditi...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.8.5.453

    authors: Petrillo J,Cairns J

    更新日期:2008-10-01 00:00:00

  • Person tradeoffs and the problem of risk.

    abstract::Recently, the person tradeoff method has received much attention because it directs one to value health improvements of those other than one's self. As a result, several researchers have suggested that the person tradeoff measures preferences in pharmaceutical and health economic analysis more accurately than the stan...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.5.6.677

    authors: Doctor JN,Miyamoto JM

    更新日期:2005-12-01 00:00:00

  • Development of a conceptual model evaluating the humanistic and economic burden of Crohn's disease: implications for patient-reported outcomes measurement and economic evaluation.

    abstract::The primary objective of this review is to develop a conceptual model for Crohn's disease (CD) outlining the disease burden for patients, healthcare systems and wider society, as reported in the scientific literature. A search was conducted using MEDLINE, PsycINFO, EconLit, Health Economic Evaluation Database and Cent...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.2015.1045883

    authors: Gater A,Kitchen H,Heron L,Pollard C,Håkan-Bloch J,Højbjerre L,Hansen BB,Strandberg-Larsen M

    更新日期:2015-01-01 00:00:00